EP
ALLO icon

Essential Partners’s Allogene Therapeutics ALLO Stock Holding History

Essential Partners’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.51K Sell
2,170
-17,240
-89% -$37.9K ﹤0.01% 1594
2026
Q1 		$47.4K Buy
19,410
+16,309
+526% +$32.7K 0.02% 615
2025
Q4 		$4.25K Sell
3,101
-4,577
-60% -$6.04K ﹤0.01% 1496
2025
Q3 		$9.52K Buy
+7,678
New +$9.15K ﹤0.01% 1170

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Essential Partners's ALLO Position: Q2 2026 in Review

Essential Partners reduced its Allogene Therapeutics (ALLO) stake by 89% in Q2 2026, selling an estimated $37.9K and leaving 2,170 shares worth $4.51K. The position accounts for ﹤0.01% of the portfolio, ranked #1594.

Essential Partners first reported a position in ALLO in Q3 2025 and has held it in 4 quarters since. The position peaked at $47.4K in Q1 2026. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Essential Partners held 2,170 shares of Allogene Therapeutics worth $4.51K as of Q2 2026.
  • Essential Partners sold 17,240 Allogene Therapeutics shares in Q2 2026, an estimated $37.9K.
  • Allogene Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1594 holding.
  • Essential Partners first reported a position in Allogene Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Essential Partners's Allogene Therapeutics position peaked at $47.4K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.